 |
 |  |  |  |
CR011-vcMMAE
CR014-vcMMAE
CR012
CR002
CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
CuraGen Reports First Quarter 2008 Financial Results
CuraGen Sells Ownership of Belinostat to TopoTarget A/S
| Project | Modality | Indication | Animal Validation | Preclinical | Phase I | Phase Ib | Phase II | Phase III |
| Oncology | ||||||||
| CR011-vcMMAE | Antibody-drug conjugate | Metastatic Melanoma |  | | | |  | |
| Breast Cancer | | | ||||||
| Brain Tumors | | | ||||||
| CR014-vcMMAE | Antibody-drug conjugate | Oncology | | | ||||
| CR012 | Antibody | Oncology | | | ||||
| Inflammatory Diseases | ||||||||
| CR002 | Antibody | Kidney Inflamation | | | | | | |
Stage definitions: Preclinical - product activity has been shown in animal models and preparations are being made for clinical development; Phase I and beyond - clinical development. The above listed products are investigational. CuraGen has not received marketing approval for any of its products.